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Upregulation of protease-activated receptor-2 in keratinocytes by epidermal vascular endothelial growth factor in vitro and in vivo 1 | BACKGROUND
Melasma is a common acquired hypermelanosis histologically characterized by increased and widely dispersed melanosomes in the keratinocytes (S1). Recent studies showed that dermal vessels and vascular endothelial growth factor (VEGF) are increased in melasma lesional skin compared to perilesional normal skin.
1,2 Moreover, laser treatments, which target the vessels by inducing thermal energy (S2), not only induce clinical improvement of melasma but also decrease VEGF expression on the melasma lesional skin.
3-5
Although the exact mechanism is unclear, these findings suggest the role of vascular structure in the development or maintenance of melasma.
VEGF is an important cytokine in the regulation of endothelial cell proliferation, migration and permeability (S3, S4). VEGF receptors are expressed not only on the endothelial cells but also on the nonendothelial cell types, such as keratinocytes and melanocytes (S5, S6).
Epidermal VEGF, which is thought to be constitutively produced by keratinocytes, is upregulated in various skin conditions, such as psoriasis, wound healing, atopic dermatitis and other states of increased skin angiogenesis (S7-9). These findings suggest that elevated VEGF may play diverse roles via autocrine or paracrine mode among keratinocytes and other types of cells in the skin.
Protease-activated receptor-2 (PAR-2) is a seven-transmembrane G-protein-coupled receptor that is activated by serine protease cleavage. In the epidermis, PAR-2 is expressed in keratinocytes (S10),
but not in melanocytes, and has been shown to be involved in melanosome transfer from melanocytes to keratinocytes. 6 Several studies demonstrated the role of PAR-2 signalling in the process of pigmentation in various experimental conditions (S11-14). In addition, downregulated PAR-2 expression was reported in vitiligo lesional skin, which is associated with melanin loss in keratinocytes. 
| QUESTIONS ADDRESSED
The aim of this study is to determine the expression of PAR-2 in lesional skin of melasma patient with different underlying telangiectasia. Moreover, we also evaluate the effect of VEGF on the expression of PAR-2 in keratinocyte in vivo and in vitro.
| EXPERIMENTAL DESIGN
Nineteen melasma patients were retrospectively evaluated for clinical telangiectatic erythema at pigmented lesion by reviewing clinical photographs. PAR-2 expression at the lesional epidermis was assessed by immunofluorescence stain using anti-PAR-2 antibody.
The intensity of erythema and PAR-2 stain was arbitrarily assessed 12, 24 and 48 hour) and different doses (12.5, 25, 50 and 100 ng/mL).
PAR-2 protein levels were measured in cultured keratinocytes after treatment with VEGF (12.5, 25, 50 and 100 ng/mL) for 48 hours. In a mouse model, intradermal injection of VEGF (5, 50 and 125 ng/mL) or PBS was applied once a day for three consecutive days. The expression levels of PAR-2 in VEGF-treated mouse skin were evaluated at one day after the final injection using immunofluorescence analysis and RT-PCR. The materials and methods are described in the online supplementary material (Appendix S1).
| RESULTS
In retrospective evaluation of PAR-2 expression and clinical telangiectatic erythema of melasma patients, PAR-2 was expressed on the epidermis, especially on the lower spinous layer and basal layer, where the keratinocytes are in contact with melanocytes.
Although the expressions of PAR-2 were different between the patients, patients who showed clinically more prominent telangiectatic erythema revealed greater PAR-2 staining intensity ( Figure 1 ).
In cocultured cells, PAR-2 mRNA levels were elevated with statistical significance at 24 hours after treatment with 50 ng/mL of VEGF (Figure 2A ). After treatment with different doses of VEGF for 24 hours, the mRNA levels of PAR-2 significantly increased to more than threefold that of the controls after treatment with 25 ng/ mL and 50 ng/mL of VEGF, and the increase was found to have occurred in a dose-dependent manner ( Figure 2B ). Upregulation of PAR-2 by VEGF treatment was also evident in cultured keratinocytes ( Figure S2 ). In mouse model, the mRNA levels of PAR-2 significantly increased in the skin of mice injected with 50 and 125 ng/ mL of VEGF than in the PBS-injected mouse skin ( Figure 2C ). This finding was further confirmed by immunofluorescence analysis ( Figure 2D ).
| CONCLUSIONS
The relationship between vascular structure and pigmentation has been emphasized by accumulating clinical evidences. In addition to melasma, lesional skin of acquired bilateral telangiectatic macules and other benign vascular skin lesions also showed hyperpigmentation as well as vascular proliferation and telangiectasia (S15). 8 Moreover, recent study demonstrated that endothelin-1, which is released by F I G U R E 2 VEGF upregulates the expression of PAR-2 in vivo and in vitro. A, The mRNA levels of PAR-2 at different time points (3, 6, 12 and 24 h) after VEGF (50 ng/mL) treatment were measured using RT-PCR in cocultured keratinocytes and melanocytes. PAR-2 mRNA levels increased to more than twice that of the controls at 3 h and more than four times that of the controls at 24 h after VEGF treatment (50 ng/mL). The differences were statistically significant. Error bars represent SEM (*P<.05). B, Cocultured melanocytes and keratinocytes were treated with different doses (12.5, 25, 50 and 100 ng/mL) of VEGF. The mRNA levels of PAR-2 significantly increased 24 h after treatment with 25 ng/mL and 50 ng/mL VEGF, and the increase was found to occur in a dose-dependent manner.
Error bars represent SEM (*P<.05). C, VEGF at different doses (5, 50 and 125 ng/mL) or PBS was injected into the intradermal space on the back skin of C57BL/6 mice once a day for 3 d. Then, PAR-2 mRNA levels in mouse skin were measured using RT-PCR. VEGFtreated mouse skin showed elevated PAR-2 mRNA levels over the PBS-treated mouse skin. The increase in PAR-2 mRNA levels in skin treated with 50 and 125 ng/mL of VEGF showed statistical significance compared to the controls. Error bars represent SEM (**P<.01; ***P<.001). D, Upregulation of PAR-2 in VEGF-treated mouse skin was further confirmed by immunofluorescence analysis. In VEGF-treated skin, epidermal keratinocytes showed higher level of PAR-2 compared to PBS-treated skin. Scale bar represents 20 μm endothelial cells, induced melanogenesis in epidermal melanocyte. 8 However, the role of other vessel-related molecules on the skin pigmentation is poorly understood.
Although several treatment options are suggested, treating melasma is challenging due to recurrence after treatment. These distinct clinical features of melasma could be explained by the effects of locally increased molecules and cells, including mast cells, fibroblasts, SCF, c-kit and VEGF (S16, S17). 1,2 Lasers, which coagulate the vessels by inducing thermal energy, such as pulsed-dye laser and copper bromide laser, have been reported as effective modality in clearing melasma and reducing recurrence of melasma. 3, 9 Besides, a copper bromide laser not only induces clinical improvement of melasma but also decreases VEGF expression on the melasma lesional skin. 3 However, the precise role of VEGF in the hyperpigmentary skin diseases including melasma is unclear.
In our study, VEGF treatment significantly increased PAR-2 expression in vitro and in vivo. Interestingly, the patients with clinically prominent telangiectatic erythema confined to hyperpig- 
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